Clinical trial
Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With…
NCT00410462 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Unknown status
Key facts
| NCT number | NCT00410462 |
|---|---|
| Title | Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma |
| Official title | Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Sarcoma, Small Intestine Cancer |
| Intervention type | Drug |
| Interventions | brostallicin, doxorubicin hydrochloride |
| Enrollment | 118 |
| Start date | Oct 1, 2006 |
| Primary completion | Sep 1, 2008 |
| First posted | Dec 13, 2006 |
| Last update posted | Aug 8, 2014 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: